Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]

Anónimo. Soluciones de hidroxietil-almidón: recomendación de suspensión de comercialización. Recomendaciones del Comité para la Evaluación de Riesgos en Farmacovigilancia europeo (PRAC). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:15 de enero. [Ref.ID 102444]

Anónimo. FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. FDA U.S. Food and Drug Administration 2013:24 de junio. [Ref.ID 95650]

Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013;346:1212. [Ref.ID 95405]

Prowle JR, Pearse RM. Is it the end of the road for synthetic starches in critical illness?. BMJ 2013;346:10. [Ref.ID 95404]

Myburgh J, Finfer S, Billot L. Hydroxyethyl starch or saline in intensive care. Author/editor response. N Engl J Med 2013;368:775. [Ref.ID 94970]

Raghunathan K, Shaw A. Hydroxyethyl starch or saline in intensive care. N Engl J Med 2013;368:774-5. [Ref.ID 94969]

Guidet B. Hydroxyethyl starch or saline in intensive care. N Engl J Med 2013;368:774. [Ref.ID 94968]

Antonelli M, Sandroni C. Hydroxyethyl starch for intravenous volume replacement: more harm than benefit. JAMA 2013;309:723-4. [Ref.ID 94959]

Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a sytematic review and meta-analysis. JAMA 2013;309:678-88. [Ref.ID 94957]

Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SAR, for the CHEST Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012;367:1901-11. [Ref.ID 94068]

Shi XY, Zou Z, He X-Y, Xu HT, Yuan HB, Liu H. Hydroxyethyl starch for cardiovascular surgery: a systematic review of randomized controlled trials. Eur J Clin Pharmacol 2011;67:767-82. [Ref.ID 91081]

Ebo DG, Fisher MM, Hagendorens MM, Bridts CH, Stevens WJ. Anaphylaxis during anaesthesia: diagnostic approach. Allergy 2007;62:471-87. [Ref.ID 78290]

Boldt J. Hydroxyethylstarch as a risk factor for acute renal failure: is a chantge of clinical practice indicated?. Drug Saf 2002;25:837-46. [Ref.ID 63498]

Bernal W, Wendon JA. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Lancet 2001;358:583. [Ref.ID 58259]

Schortgen F, Brochard L. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Authors' reply. Lancet 2001;358:582. [Ref.ID 58258]

Boldt J. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Lancet 2001;358:581-2. [Ref.ID 58257]

Godet G. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Lancet 2001;358:581. [Ref.ID 58256]

Gosling P, Rittoo D, Manji M, Mahmood A, Vohra R. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Lancet 2001;358:581. [Ref.ID 58255]

Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-6. [Ref.ID 55760]